News Announcement

Abbott India: Announcement under Regulation 30 (LODR)-Press Release / Media Release

Abbott partners with Novo Nordisk India to launch Extensior broadening access to Semaglutide (Ozempic) for advanced diabetes management.

Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.